Richard D.  Pilnik net worth and biography

Richard Pilnik Biography and Net Worth

Richard Pilnik has served as a member of our board of directors since May 2009. Mr. Pilnik serves as our Chairman of the Board. 

Mr. Pilnik has served as the President and member of the board of directors of Vigor Medical Services, Inc. since May 2017.  From December 2015 to November 2017, Mr. Pilnik served as a member of the board of directors of Chiltern International Limited, a private leading mid-tier Clinical Research Organization, and was Chairman of the Board from April 2016 to November 2017.  Mr. Pilnik has a 30-year career in healthcare at Eli Lilly and Company and Quintiles Transnational Corp., a global pioneer in pharmaceutical services.  From April 2009 to June 2014, Mr. Pilnik served as Executive Vice President and President of Quintiles Commercial Solutions, an outsourcing business to over 70 pharma and biotech companies.  Prior to that, he spent 25 years at Eli Lilly and Company where he held several leadership positions, most recently as Group Vice President and Chief Marketing Officer from May 2006 to July 2008.  Mr. Pilnik was directly responsible for commercial strategy, market research, new product planning and the medical marketing interaction.  From December 2000 to May 2006, Mr. Pilnik served as President of Eli Lilly Europe, Middle East and Africa and the Commonwealth of Independent States, a regional organization of former Soviet Republics, and oversaw 50 countries and positioned Eli Lilly as the fastest growing pharmaceutical company in the region.  Mr. Pilnik also held several marketing and sales management positions in the United States, Europe and Latin America.  

Mr. Pilnik currently serves on the board of directors of Vigor Medical Systems, Inc., NuSirt, an early-stage biopharma, and the Duke University Fuqua School of Business.  Mr. Pilnik previously served on the board of directors of Elan Pharmaceuticals, Chiltern International, the largest mid-size Clinical Research Organization, and Certara, L.P., a private biotech company focused on drug development modeling and biosimulation.  Mr. Pilnik holds a Bachelor of Arts in Economics from Duke University and an MBA from the Kellogg School of Management at Northwestern University.

How do I contact Richard D. Pilnik?

The corporate mailing address for Mr. Pilnik and other DiaMedica Therapeutics executives is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. DiaMedica Therapeutics can also be reached via phone at (763) 496-5454 and via email at [email protected]. Learn More on Richard D. Pilnik's contact information.

Has Richard D. Pilnik been buying or selling shares of DiaMedica Therapeutics?

Richard D. Pilnik has not been actively trading shares of DiaMedica Therapeutics during the past quarter. Learn More on Richard D. Pilnik's trading history.

Who are DiaMedica Therapeutics' active insiders?

DiaMedica Therapeutics' insider roster includes Harry Alcorn, Jr. (VP), Dietrich Pauls (CEO), and Richard Pilnik (Director). Learn More on DiaMedica Therapeutics' active insiders.

Are insiders buying or selling shares of DiaMedica Therapeutics?

During the last twelve months, DiaMedica Therapeutics insiders bought shares 6 times. They purchased a total of 2,065,489 shares worth more than $6,243,249.61. The most recent insider tranaction occured on June, 23rd when Director Randall Michael Giuffre bought 65,000 shares worth more than $254,150.00. Insiders at DiaMedica Therapeutics own 6.5% of the company. Learn More about insider trades at DiaMedica Therapeutics.

Information on this page was last updated on 6/23/2023.

Richard D. Pilnik Insider Trading History at DiaMedica Therapeutics

See Full Table

Richard D. Pilnik Buying and Selling Activity at DiaMedica Therapeutics

This chart shows Richard D. Pilnik's buying and selling at DiaMedica Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

DiaMedica Therapeutics Company Overview

DiaMedica Therapeutics logo
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. The company develops treatments for neurological disorders and cardio-renal disease. Its lead candidate is DM199, a pharmaceutically active recombinant form of the kallikrein-1 protein for the treatment of acute ischemic stroke and other vascular diseases. It is also developing DM300 that is in preclinical stage of development for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Read More

Today's Range

Now: $2.77
Low: $2.73
High: $2.81

50 Day Range

MA: $2.91
Low: $2.58
High: $3.23

2 Week Range

Now: $2.77
Low: $1.46
High: $4.75

Volume

20,711 shs

Average Volume

41,905 shs

Market Capitalization

$105.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.72